This is a study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PRX-03140 administered orally once daily for 14 days in subjects with mild Alzheimer's Disease who are using a stable, well-tolerated 10 mg dose of Aricept (donepezil) but continue to experience worsening AD symptoms.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
80
California Clinical Trials Medical Group, Inc
Paramount, California, United States
Southwest CLinical Research
Rancho Mirage, California, United States
Safety and tolerability of PRX-03140 during 2 weeks of treatment.
Electroencephalogram (EEG) changes through 14 days of treatment.
Changes in cognition after 2 weeks of treatment.
Blood concentrations of PRX-03140 and Aricept during 14 days of treatment.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pacific Research Network, Inc
San Diego, California, United States
San Francisco Clinical Research Center
San Francisco, California, United States
Torrance Clinical Research
Torrance, California, United States
Research Center for Clinical Studies
Darien, Connecticut, United States
Miami Jewish Home and Hospital for the Aged
Miami, Florida, United States
Berma Research
Plantation, Florida, United States
Comprehensive NeuroScience, Inc
St. Petersburg, Florida, United States
Meridien Research
St. Petersburg, Florida, United States
...and 7 more locations